Skip to main content
SpringerLink
Log in

The Association between Conventional Antidepressants and the Metabolic Syndrome

A Review of the Evidence and Clinical Implications

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Major depressive disorder is a prevalent recurrent medical syndrome associated with inter-episodic dysfunction. The metabolic syndrome is comprised of several established risk factors for cardiovascular disease (i.e. abdominal obesity, dyslipidaemia, dysglycaemia and hypertension). The criterion items of the metabolic syndrome collectively represent a multi-dimensional risk factor for cardiovascular disease and type 2 diabetes mellitus. Extant evidence indicates that both major depressive disorder and the metabolic syndrome, albeit distinct, often co-occur and are possibly subserved by overlapping pathophysiology and causative mechanisms. Conventional antidepressants exert variable effects on constituent elements of the metabolic syndrome, inviting the need for careful consideration prior to treatment selection and sequencing. Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 Jan 16; 287(3): 356–9

    Article  PubMed  Google Scholar 

  2. Gans RO. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am 2006 Jul; 90(4): 573–91

    Article  PubMed  Google Scholar 

  3. McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009 Feb; 9(1): 51–9

    Article  PubMed  Google Scholar 

  4. Kooy FH. Hyperglycemia in mental disorders. Brain 1919; 42: 214–89

    Article  CAS  Google Scholar 

  5. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001 Jun; 24(6): 1069–78

    Article  PubMed  CAS  Google Scholar 

  6. Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes: an epidemiological evaluation. Diabetes Care 1993 Aug; 16(8): 1167–78

    Article  PubMed  CAS  Google Scholar 

  7. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000 Jul; 23(7): 934–42

    Article  PubMed  CAS  Google Scholar 

  8. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005 Apr; 118 Suppl. 2: 15S–22S

    PubMed  Google Scholar 

  9. Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006 Sep; 67(9): 1422–7

    Article  PubMed  Google Scholar 

  10. McCaffery JM, Niaura R, Todaro JF, et al. Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute twin study. Psychosom Med 2003 May; 65(3): 490–7

    Article  PubMed  Google Scholar 

  11. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as “metabolic syndrome type II”? Ann Clin Psychiatry 2007 Oct; 19(4): 257–64

    Article  PubMed  Google Scholar 

  12. Toalson P, Ahmed S, Hardy T, et al. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 2004; 6(4): 152–8

    Article  PubMed  Google Scholar 

  13. Toker S, Shirom A, Melamed S. Depression and the metabolic syndrome: gender-dependent associations. Depress Anxiety 2008; 25(8): 661–9

    Article  PubMed  Google Scholar 

  14. Weber-Hamann B, Werner M, Hentschel F, et al. Metabolic changes in elderly patients with major depression: evidence for increased accumulation of visceral fat at follow-up. Psychoneuroendocrinology 2006 Apr; 31(3): 347–54

    Article  PubMed  CAS  Google Scholar 

  15. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, et al. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-Year follow-up study. J Clin Psychiatry 2008 Feb; 69(2): 178–82

    Article  PubMed  Google Scholar 

  16. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007 Dec; 29(4): 330–6

    Article  PubMed  Google Scholar 

  17. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO Study Group. Diabetes Care 1996 Sep; 19(9): 920–6

    Article  PubMed  CAS  Google Scholar 

  18. Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002 Dec; 51(12): 1573–7

    Article  PubMed  CAS  Google Scholar 

  19. McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry 2002; 63 Suppl. 3: 15–20

    Google Scholar 

  20. McIntyre RS, Konarski JZ, Keck PE. Psychotropic-induced weight gain: liability, mechanisms and treatment approaches. In: McElroy SL, Allison DB, Bray GA, editors. Obesity and mental disorders. New York: Taylor & Francis, 2005: 307–52

    Google Scholar 

  21. McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on lipid homeostasis: a cardiac safety concern?Expert Opin Drug Saf 2006 Jul; 5(4): 523–37

    Article  PubMed  CAS  Google Scholar 

  22. McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006 Jan; 5(1): 157–68

    Article  PubMed  CAS  Google Scholar 

  23. van Praag HM, Leijnse B. Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of anti-depressive drugs of the hydrazine type. Psychopharmacologia 1965 Jun 1; 8(1): 67–78

    Article  PubMed  Google Scholar 

  24. van Pragg H, Leijnse B. The influence of some antidepressives of the hydrazine type on the glucose metabolism in depressed patients. Clin Chim Acta 1963 May; 8: 466–75

    Article  Google Scholar 

  25. Van Praag HM, Leijnse B. The xylose metabolism in depressed patients and its alterations under the influence of antidepressive hydrazines. Clinica Chimica Acta 1965; 11: 13–23

    Article  Google Scholar 

  26. Cantu TG, Korek JS. Monoamine oxidase inhibitors and weight gain. Drug Intell Clin Pharm 1988 Oct; 22(10): 755–9

    PubMed  CAS  Google Scholar 

  27. Davidson J, Turnbull CD. The effects of isocarboxazid on blood pressure and pulse. J Clin Psychopharmacol 1986 Jun; 6(3): 139–43

    Article  PubMed  CAS  Google Scholar 

  28. Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors: part I. A comparative study. J Clin Psychopharmacol 1984 Oct; 4(5): 270–8

    CAS  Google Scholar 

  29. Kennedy SH, Lam RW, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: introduction. J Affect Disord 2009 Oct; 117 Suppl. 1: S1–2

    Article  PubMed  Google Scholar 

  30. Nair NP, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord 1995 Jan 11; 33(1): 1–9

    Article  PubMed  CAS  Google Scholar 

  31. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002 Mar; 47(2): 174–80

    PubMed  CAS  Google Scholar 

  32. Vaz-Serra A, Figueira ML, Firmino H, et al. Multicenter double-blind study of moclobemide and maprotiline. Clin Neuropharmacol 1994; 17 Suppl. 1: S38–49

    Article  PubMed  Google Scholar 

  33. Bakish D, Bradwejn J, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) 1992; 106 Suppl. : S98–101

    Article  Google Scholar 

  34. Moll E, Neumann N, Schmid-Burgk W, et al. Safety and efficacy during long-term treatment with moclobemide. Clin Neuropharmacol 1994; 17 Suppl. 1: S74–87

    Article  PubMed  Google Scholar 

  35. Ghaeli P, Shahsavand E, Mesbahi M, et al. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004 Aug; 24(4): 386–8

    Article  PubMed  CAS  Google Scholar 

  36. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997 May; 59(3): 241–50

    PubMed  CAS  Google Scholar 

  37. Moosa MY, Panz VR, Jeenah FY, et al. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003 Dec; 23(6): 549–52

    Article  PubMed  CAS  Google Scholar 

  38. Yeragani VK, Pohl R, Balon R, et al. Increased serum total cholesterol to HDL-cholesterol ratio after imipramine. Psychiatry Res 1990 May; 32(2): 207–9

    Article  PubMed  CAS  Google Scholar 

  39. Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000 Jul; 23(1): 13–9

    Article  PubMed  CAS  Google Scholar 

  40. Berilgen MS, Bulut S, Gonen M, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005 Nov; 25(11): 1048–53

    Article  PubMed  CAS  Google Scholar 

  41. Paykel ES, Mueller PS, De la Vergne PM. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br J Psychiatry 1973 Nov; 123(576): 501–7

    Article  PubMed  CAS  Google Scholar 

  42. Sansone RA, Wiederman MW, Shrader JA. Naturalistic study of the weight effects of amitriptyline, fluoxetine, and sertraline in an outpatient medical setting. J Clin Psychopharmacol 2000 Apr; 20(2): 272–4

    Article  PubMed  CAS  Google Scholar 

  43. Kopf D, Westphal S, Luley CW, et al. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol 2004 Oct; 24(5): 527–31

    Article  PubMed  CAS  Google Scholar 

  44. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988 Dec; 26(3): 265–71

    Article  PubMed  CAS  Google Scholar 

  45. Berken GH, Weinstein DO, Stern WC. Weight gain: a side-effect of tricyclic antidepressants. J Affect Disord 1984 Oct; 7(2): 133–8

    Article  PubMed  CAS  Google Scholar 

  46. Frank E, Kupfer DJ, Buhari A, et al. Imipramine and weight gain during the long-term treatment of recurrent depression. J Affect Disord 1992 Sep; 26(1): 65–72

    Article  PubMed  CAS  Google Scholar 

  47. Kupfer DJ, Coble PA, Rubinstein D. Changes in weight during treatment for depression. Psychosom Med 1979 Nov; 41(7): 535–44

    PubMed  CAS  Google Scholar 

  48. Levitt AJ, Joffe RT, Esche I, et al. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987 Jan; 48(1): 27–8

    PubMed  CAS  Google Scholar 

  49. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001 Apr; 62(4): 256–60

    Article  PubMed  CAS  Google Scholar 

  50. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994 Jun;14(3): 170–9

    Article  PubMed  CAS  Google Scholar 

  51. Perry PJ, Garvey MJ, Dunner DL, et al. A report of trazodone-associated laboratory abnormalities. Ther Drug Monit 1990 Nov; 12(6): 517–9

    Article  PubMed  CAS  Google Scholar 

  52. Maheux P, Ducros F, Bourque J, et al. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997 Feb; 21(2): 97–102

    Article  PubMed  CAS  Google Scholar 

  53. O’Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994 Jan; 11(1): 105–10

    Article  PubMed  Google Scholar 

  54. Potter van Loon BJ, Radder JK, Frolich M, et al. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992 Dec; 16 Suppl. 4: S55–61

    Google Scholar 

  55. Gray DS, Fujioka K, Devine W, et al. A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord 1992 Dec; 16 Suppl. 4: S67–72

    PubMed  Google Scholar 

  56. Weber-Hamann B, Gilles M, Lederbogen F, et al. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006 Dec; 67(12): 1856–61

    Article  PubMed  CAS  Google Scholar 

  57. Chen YC, Shen YC, Hung YJ, et al. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 2007 Nov; 103(1–3): 257–61

    Article  PubMed  CAS  Google Scholar 

  58. Lara N, Baker GB, Archer SL, et al. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry 2003 Dec; 64(12): 1455–9

    Article  PubMed  CAS  Google Scholar 

  59. Hewer W, Rost W, Gattaz WF. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 1995; 246(1): 1–6

    Article  PubMed  CAS  Google Scholar 

  60. Kauffman RP, Castracane VD, White DL, et al. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol 2005 Sep; 21(3): 129–37

    Article  PubMed  CAS  Google Scholar 

  61. Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000 Dec; 20(6): 645–52

    Article  PubMed  CAS  Google Scholar 

  62. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000 Nov; 61(11): 863–7

    Article  PubMed  CAS  Google Scholar 

  63. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998 Mar; 13(2): 63–73

    Article  PubMed  CAS  Google Scholar 

  64. Daubresse JC, Kolanowski J, Krzentowski G, et al. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996 Jul; 4(4): 391–6

    Article  PubMed  CAS  Google Scholar 

  65. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999 Aug; 156(8): 1170–6

    PubMed  CAS  Google Scholar 

  66. Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001 Apr; 64(1): 43–51

    Article  PubMed  CAS  Google Scholar 

  67. Seo HJ, Jung YE, Woo YS, et al. Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Hum Psychopharmacol 2009 Mar; 24(2): 135–43

    Article  PubMed  Google Scholar 

  68. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep; 65(9): 1190–6

    Article  PubMed  CAS  Google Scholar 

  69. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005 Apr; 17(2): 65–9

    Article  PubMed  Google Scholar 

  70. Gulseren L, Gulseren S, Hekimsoy Z, et al. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005 Mar; 36(2): 159–65

    Article  PubMed  CAS  Google Scholar 

  71. Ljung T, Ahlberg AC, Holm G, et al. Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study. J Intern Med 2001 Sep; 250(3): 219–24

    Article  PubMed  CAS  Google Scholar 

  72. Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004 Jun; 65(6): 766–71

    Article  PubMed  CAS  Google Scholar 

  73. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 May; 20(3): 131–7

    Article  PubMed  Google Scholar 

  74. Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract 2003 May 14; 4: 7

    Article  PubMed  Google Scholar 

  75. Sonawalla SB, Papakostas GI, Petersen TJ, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 2002 Jul; 43(4): 310–6

    Article  PubMed  CAS  Google Scholar 

  76. Weber-Hamann B, Kratzsch J, Kopf D, et al. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res 2007 Apr; 41(3–4): 344–50

    Article  PubMed  Google Scholar 

  77. Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007 Jan; 30(1): 21–6

    Article  PubMed  CAS  Google Scholar 

  78. Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007 Sep; 8(6): 503–13

    Article  PubMed  Google Scholar 

  79. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008 Sep; 23(5): 243–53

    Article  PubMed  Google Scholar 

  80. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 Apr; 63(4): 308–15

    Article  PubMed  CAS  Google Scholar 

  81. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007 Nov; 68(11): 1663–72

    Article  PubMed  Google Scholar 

  82. Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007 Aug; 68(8): 1246–56

    Article  PubMed  CAS  Google Scholar 

  83. Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 2007 Dec 15; 62(12): 1371–9

    Article  PubMed  CAS  Google Scholar 

  84. Tourian KA, Leurent C, Graepel J, et al. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry 2010; 12 (1): PCC.08m00746

  85. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 Dec; 14(6): 457–70

    Article  PubMed  CAS  Google Scholar 

  86. Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005 Feb; 66(2): 238–47

    Article  PubMed  CAS  Google Scholar 

  87. Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006 Sep; 7(5): 373–85

    Article  PubMed  Google Scholar 

  88. Wohlreich MM, Mallinckrodt CH, Prakash A, et al. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety 2007; 24(1): 41–52

    Article  PubMed  CAS  Google Scholar 

  89. Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 2006 Jan; 29(1): 170

    Article  PubMed  Google Scholar 

  90. Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003 Aug; 64(8): 883–9

    Article  PubMed  CAS  Google Scholar 

  91. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67: 421–4

    Article  PubMed  CAS  Google Scholar 

  92. Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999 Jan; 60(1): 45–9

    Article  PubMed  CAS  Google Scholar 

  93. Danileviciute V, Sveikata A, Adomaitiene V, et al. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina (Kaunas) 2009; 45(10): 778–84

    Google Scholar 

  94. Hennings JM, Ising M, Grautoff S, et al. Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. Exp Clin Endocrinol Diabetes 2010 Feb; 118(2): 98–100

    Article  PubMed  CAS  Google Scholar 

  95. Fisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapine-induced weight gain. Am J Psychiatry 2003 Apr; 160(4): 797

    Article  PubMed  Google Scholar 

  96. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001 Sep; 9(9): 544–51

    Article  PubMed  CAS  Google Scholar 

  97. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002 Oct; 10(10): 1049–56

    CAS  Google Scholar 

  98. Croft H, Settle Jr E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr; 21(4): 643–58

    Article  PubMed  CAS  Google Scholar 

  99. Feighner J, Hendrickson G, Miller L, et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986 Feb; 6(1): 27–32

    Article  PubMed  CAS  Google Scholar 

  100. Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008 Jun; 28(3): 302–7

    Article  PubMed  CAS  Google Scholar 

  101. Lustman PJ, Williams MM, Sayuk GS, et al. Factors influencing glycemic control in type 2 diabetes during acute-and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007 Mar; 30(3): 459–66

    Article  PubMed  CAS  Google Scholar 

  102. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001 Mar; 13(1): 31–41

    PubMed  CAS  Google Scholar 

  103. Lustman PJ, Clouse RE. Treatment of depression in diabetes: impact on mood and medical outcome. J Psychosom Res 2002 Oct; 53(4): 917–24

    Article  PubMed  Google Scholar 

  104. Lustman PJ, Clouse RE. Depression in diabetes: the chicken or the egg? Psychosom Med 2007 May; 69(4): 297–9

    Article  PubMed  Google Scholar 

  105. McIntyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005 Apr; 17(2): 83–93

    Article  PubMed  Google Scholar 

  106. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996 Jan; 37(1): 68–73

    Article  PubMed  CAS  Google Scholar 

  107. Braceland JF, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1946; 102: 108–10

    Google Scholar 

  108. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989 Mar 4; 1(8636): 495

    Article  PubMed  CAS  Google Scholar 

  109. Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009 May; 166(5): 591–8

    Article  PubMed  Google Scholar 

  110. Raskin JWFWJFSCCJW. Duloxetine does not affect glycemic control or lipid profiles in patients with diabetic neuropathic pain. Presented at the American Diabetes Association; 2004 Jun 4–8; Orlando (FL)

  111. Othmer E, Othmer SC, Stern WC, et al. Long-term efficacy and safety of bupropion. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 153–6

    PubMed  CAS  Google Scholar 

  112. Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000 Oct; 49(10): 1255–60

    Article  PubMed  CAS  Google Scholar 

  113. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-421

  114. Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998 Oct; 19 Suppl. M: M8–14

    PubMed  Google Scholar 

  115. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994 Feb 5; 308(6925): 367–72

    Article  PubMed  CAS  Google Scholar 

  116. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998 Feb 26; 81(4A): 7B–12B

    Article  PubMed  CAS  Google Scholar 

  117. Canadian Pharmacist Association. Compendium of pharmaceuticals and specialties. Ottawa (ON): Canadian Pharmacist Association, 2007

    Google Scholar 

  118. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005 Feb; 62(2): 190–8

    Article  PubMed  CAS  Google Scholar 

  119. Visser M, Seidell JC, Koppeschaar HP, et al. No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obes Res 1994 Mar; 2(2): 152–9

    Article  PubMed  CAS  Google Scholar 

  120. Fisar Z, Anders M, Tvrzicka E, et al. Effect of long-term administration of antidepressants on the lipid composition of brain plasma membranes. Gen Physiol Biophys 2005 Jun; 24(2): 221–36

    PubMed  CAS  Google Scholar 

  121. Masuda Y, Ohnuma S, Sugiyama T. Relationship between antidepressants and glycolipids in the forced swimming test in mice. Methods Find Exp Clin Pharmacol 2000 Nov; 22(9): 667–70

    Article  PubMed  CAS  Google Scholar 

  122. Davidson KW, Kupfer DJ, Bigger JT, et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med 2006 Sep; 68(5): 645–50

    Article  PubMed  CAS  Google Scholar 

  123. Frasure-Smith N, Lesperance F. Recent evidence linking coronary heart disease and depression. Can J Psychiatry 2006 Oct; 51(12): 730–7

    PubMed  Google Scholar 

  124. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998 Jan; 155(1): 4–11

    PubMed  CAS  Google Scholar 

  125. Dobbels F, De GS, Vanhees L, et al. Depression and the heart: a systematic overview of definition, measurement, consequences and treatment of depression in cardiovascular disease. Eur J Cardiovasc Nurs 2002 Feb; 1(1): 45–55

    Article  PubMed  Google Scholar 

  126. Kronfol Z. Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol 2002 Dec; 5(4): 333–43

    Article  PubMed  CAS  Google Scholar 

  127. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998 Jul; 55(7): 580–92

    Article  PubMed  CAS  Google Scholar 

  128. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J 2004 Mar; 25(6): 492–9

    Article  PubMed  CAS  Google Scholar 

  129. Ramasubbu R. Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases. Med Hypotheses 2002 Nov; 59(5): 537–51

    Article  PubMed  CAS  Google Scholar 

  130. Scalco AZ, Scalco MZ, Azul JB, et al. Hypertension and depression. Clinics 2005 Jun; 60(3): 241–50

    Article  PubMed  Google Scholar 

  131. Davidson K, Jonas BS, Dixon KE, et al. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary Artery Risk Development in Young Adults. Arch Intern Med 2000 May 22; 160(10): 1495–500

    Article  PubMed  CAS  Google Scholar 

  132. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006 Feb; 9(1): 29–40

    Article  PubMed  Google Scholar 

  133. Wohlreich MM, Perahia DG, Acharya N, et al. Duloxetine hepatic effects: 2006 review. Austria European Congress of Neuropsychopharmacology; 2007 Oct 13; Vienna

  134. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005 Feb; 66(2): 253–9

    Article  PubMed  Google Scholar 

  135. Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991 Apr; 148(4): 512–6

    PubMed  CAS  Google Scholar 

  136. Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders: IV. Medications and other biological treatments. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 38S–58S

    PubMed  Google Scholar 

  137. Botella-Carretero JI, Escobar-Morreale HF, Martin I, et al. Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. Horm Metab Res 2004 Mar; 36(3): 178–82

    Article  PubMed  CAS  Google Scholar 

  138. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996 Mar; 57(3): 99–104

    PubMed  CAS  Google Scholar 

  139. McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004 May; 65(5): 634–51, quiz

    Article  PubMed  Google Scholar 

  140. Pine DS, Goldstein RB, Wolk S, et al. The association between childhood depression and adulthood body mass index. Pediatrics 2001 May; 107(5): 1049–56

    Article  PubMed  CAS  Google Scholar 

  141. McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 2004; 19(6): 369–86

    Article  PubMed  Google Scholar 

  142. Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001 Mar 24; 322(7288): 716–20

    Article  PubMed  CAS  Google Scholar 

  143. Weber-Hamann B, Hentschel F, Kniest A, et al. Hyper-cortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002 Mar; 64(2): 274–7

    PubMed  Google Scholar 

  144. Hach I, Ruhl UE, Klotsche J, et al. Associations between waist circumference and depressive disorders. J Affect Disord 2006 Jun; 92(2–3): 305–8

    Article  PubMed  Google Scholar 

  145. McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry 2006; 51: 274–80

    PubMed  Google Scholar 

  146. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl. 11: 37–41

    Google Scholar 

  147. Balon R, Yeragani VK, Pohl R, et al. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder. Can J Psychiatry 1993 Feb; 38(1): 19–22

    PubMed  CAS  Google Scholar 

  148. Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005 Oct; 187: 352–9

    Article  PubMed  Google Scholar 

  149. Feiger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999 Jan; 14(1): 19–28

    Article  PubMed  CAS  Google Scholar 

  150. Frank E, Kupfer DJ, Bulik CM, et al. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord 1990 Nov; 20(3): 165–72

    Article  PubMed  CAS  Google Scholar 

  151. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety: Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999 Jan; 60(1): 22–8

    Article  PubMed  CAS  Google Scholar 

  152. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988 Oct; 8(5): 323–30

    Article  PubMed  CAS  Google Scholar 

  153. Kazes M, Danion JM, Grange D, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord 1994 Mar; 30(3): 193–207

    Article  PubMed  CAS  Google Scholar 

  154. Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003 May; 37(3): 193–220

    Article  PubMed  Google Scholar 

  155. Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry 2007 Mar 30; 31(2): 370–2

    Article  PubMed  CAS  Google Scholar 

  156. Kendall-Tackett KA. Inflammation, cardiovascular disease, and metabolic syndrome as sequelae of violence against women: the role of depression, hostility, and sleep disturbance. Trauma Violence Abuse 2007 Apr; 8(2): 117–26

    Article  PubMed  Google Scholar 

  157. Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 2002 Oct; 53(4): 873–6

    Article  PubMed  Google Scholar 

  158. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999 Jul; 4(4): 317–27

    Article  PubMed  CAS  Google Scholar 

  159. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002 May; 26(5): 643–52

    Article  PubMed  CAS  Google Scholar 

  160. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004 Dec 1; 56(11): 819–24

    Article  PubMed  CAS  Google Scholar 

  161. Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8(6): 365–70

    Article  PubMed  CAS  Google Scholar 

  162. McEwen BS, Magarinos AM, Reagan LP. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J Psychosom Res 2002 Oct; 53(4): 883–90

    Article  PubMed  Google Scholar 

  163. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999 May; 96(5): 513–23

    Article  CAS  Google Scholar 

  164. McEwen BS, Stellar E. Stress and the individual: mechanisms leading to disease. Arch Intern Med 1993 Sep 27; 153(18): 2093–101

    Article  PubMed  CAS  Google Scholar 

  165. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry 2003 Aug 1; 54(3): 200–7

    Article  PubMed  Google Scholar 

  166. Axelson DA, Doraiswamy PM, McDonald WM, et al. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 1993 May; 47(2): 163–73

    Article  PubMed  CAS  Google Scholar 

  167. Belanoff JK, Kalehzan M, Sund B, et al. Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 2001 Oct; 158(10): 1612–6

    Article  PubMed  CAS  Google Scholar 

  168. Keller J, Flores B, Gomez RG, et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006 Aug 1; 60(3): 275–81

    Article  PubMed  CAS  Google Scholar 

  169. Rebuffe-Scrive M, Walsh UA, McEwen B, et al. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol Behav 1992 Sep; 52(3): 583–90

    Article  PubMed  CAS  Google Scholar 

  170. Gil K, Radzillowicz P, Zdrojewski T, et al. Relationship between the prevalence of depressive symptoms and metabolic syndrome: results of the SOPKARD Project. Kardiol Pol 2006 May; 64(5): 464–9

    PubMed  Google Scholar 

  171. Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004 May; 66(3): 316–22

    Article  PubMed  Google Scholar 

  172. Vaccarino V, McClure C, Johnson BD, et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med 2008 Jan; 70(1): 40–8

    Article  PubMed  Google Scholar 

  173. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 2002 Apr; 68(2–3): 167–81

    Article  PubMed  CAS  Google Scholar 

  174. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001 Sep; 58(9): 844–50

    Article  PubMed  CAS  Google Scholar 

  175. Enns MW, Swenson JR, McIntyre RS, et al. Clinical guidelines for the treatment of depressive disorders: VII. Comorbidity. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 77S–90S

    PubMed  Google Scholar 

  176. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002 Aug 14; 288(6): 701–9

    Article  PubMed  CAS  Google Scholar 

  177. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S11–4

    Article  Google Scholar 

  178. McIntyre RS. Overview of managing medical comorbidities in patients with severe mental illness. J Clin Psychiatry 2009 Jun; 70(6): e17

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Dr McIntyre has served on advisory boards for Astra Zeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen-Ortho, Solvay/Wyeth, Eli Lilly, Organon, Lundbeck, Biovail, Pfizer, Shire, Schering-Plough and Merck; has served on speaker’s bureaux for Janssen-Ortho, Astra-Zeneca, Eli Lilly, Lundbeck, Biovail and Merck; has been involved in CME activities for Astra Zeneca, Bristol-Myers Squibb, France Foundation, I3CME, Solvay/Wyeth, Physicians’ Postgraduate Press, CME Outfitters, Optum Health, Schering-Plough, Merck and Eli Lilly; has received research grants from the Stanley Medical Research Institute, the National Alliance for Research on Schizophrenia and Depression (NARSAD), Eli Lilly, Janssen-Ortho, Shire, Astra-Zeneca and Pfizer; and has received travel funds from Bristol-Myers Squibb. Dr Kennedy has received grant funding and/or consultant fees from ANS, AstraZeneca, Biovail, Boehringer Ingelheim, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Eli Lilly, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Merck Frosst, NARSAD, OMHF, OPGRS, Organon, Pfizer, Servier, the Stanley Foundation and Wyeth. Ms Soczynska has received honoraria from Organon and Wyeth. Dr Alsumaidan currently holds equity in sanofi-aventis. Drs Lo, Law, Lourenco, Park and Yoon, and Ms Woldeyohannes, Sultan and Adams, have no conflicts of interest that are directly relevant to the content of this review. No funding was received for the preparation of this review.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

    Roger S. McIntyre (Associate Professor of Psychiatry and Pharmacology, University of Toronto, Head), Mohammad Alsuwaidan & Sidney H. Kennedy

  2. Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada

    Roger S. McIntyre (Associate Professor of Psychiatry and Pharmacology, University of Toronto, Head)

  3. Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada, M5T 2S8

    Roger S. McIntyre (Associate Professor of Psychiatry and Pharmacology, University of Toronto, Head), Candy W. Y. Law, Farah Sultan, Amanda Adams, Maria Teresa Lourenco, Aaron K. S. Lo, Joanna K. Soczynska, Hanna Woldeyohannes, Mohammad Alsuwaidan, Jinju Yoon & Sidney H. Kennedy

  4. Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada

    Roger S. McIntyre (Associate Professor of Psychiatry and Pharmacology, University of Toronto, Head), Joanna K. Soczynska & Sidney H. Kennedy

  5. Department of Family and Community Medicine, University of Toronto, Ontario, Canada

    Ka Young Park

Authors
  1. Roger S. McIntyre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ka Young Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Candy W. Y. Law
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farah Sultan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amanda Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Teresa Lourenco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aaron K. S. Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joanna K. Soczynska
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hanna Woldeyohannes
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mohammad Alsuwaidan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jinju Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sidney H. Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger S. McIntyre.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

McIntyre, R.S., Park, K.Y., Law, C.W.Y. et al. The Association between Conventional Antidepressants and the Metabolic Syndrome. CNS Drugs 24, 741–753 (2010). https://doi.org/10.2165/11533280-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11533280-000000000-00000

Keywords

Search

Navigation